| Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients. | |
| | |
MedLine Citation:
|
PMID: 20016018 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: To analyse the association between plasma chemokine levels at baseline and virological response to interferon-alpha (IFN-alpha) + ribavirin in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infected patients. METHODS: We carried out a retrospective study in 109 patients. Chemokines were measured using Multiplex kits using a Luminex 100 Analyzer. Logistic regression was used to evaluate the association between plasma chemokine levels before HCV therapy and virological response at weeks 48 and 72 after starting HCV therapy. RESULTS: Fifty-seven patients out of 103 achieved end of treatment virological response (ETR). In patients achieving ETR, the baseline levels of eotaxin, MCP-1 and MCP-3 were higher than non-responder (NR) patients. Similarly, 51 patients out of 106 achieved sustained virological response (SVR). In patients achieving SVR, the baseline levels of eotaxin and MCP-1 were higher than in NR patients. Plasma levels of eotaxin, MCP-1 and MCP-3 had a significant positive association with ETR, as well as eotaxin and MCP-1 with SVR. However, after stepwise multivariate logistic regression, eotaxin was the only chemokine selected capable of predicting ETR and SVR with odds ratio (OR) of 1.016 (95% CI: 1.004-1.029) and 1.015 (95% CI: 1.002-1.027) for ETR and SVR, respectively. CONCLUSIONS: Our preliminary data suggest that plasma eotaxin levels prior to HCV antiviral therapy may be useful in predicting virological response to HCV treatment with IFN-alpha + ribavirin in HIV/HCV co-infected patients. Further experimental research is necessary to corroborate this hypothesis. |
| | |
Authors:
|
Ana Vargas; Juan Berenguer; Pilar Catal?n; Pilar Miralles; Juan Carlos L?pez; Jaime Cos?n; Salvador Resino |
Related Documents
:
|
17245458 - Hepatitis c treatment of patients with bipolar disorder: a case series. 16633948 - Lymph node enlargement during combination therapy for chronic hepatitis c with pegylate... 12945008 - High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin wi... 19701978 - Sustained virologic response following hcv eradication in two brothers with x-linked ag... 8681618 - An effectiveness community-based clinical trial of respirgard ii and fisoneb nebulizers... 9638878 - Cytomegalovirus infection in kidney transplant patients: clinical manifestations and di... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-12-16 |
Journal Detail:
|
Title: The Journal of antimicrobial chemotherapy Volume: 65 ISSN: 1460-2091 ISO Abbreviation: J. Antimicrob. Chemother. Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-01-22 Completed Date: 2010-03-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7513617 Medline TA: J Antimicrob Chemother Country: England |
Other Details:
|
Languages: eng Pagination: 303-6 Citation Subset: IM |
Affiliation:
|
Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antiviral Agents / therapeutic use* Chemokine CCL11 / blood* Female HIV Infections / complications, drug therapy* Hepatitis C, Chronic / complications, drug therapy* Humans Interferon-alpha / therapeutic use* Male Plasma / chemistry* Retrospective Studies Ribavirin / therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/CCL11 protein, human; 0/Chemokine CCL11; 0/Interferon-alpha; 36791-04-5/Ribavirin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New therapeutic strategies for raltegravir.
Next Document: Caspofungin-non-susceptible Candida isolates in cancer patients.